Consistent with the identified CD8+ T-cell-inflamed nature, MAPK pathway mutations alone, independent of tumor mutational burden (TMB), were able to identify subsets of HNSCC patients benefiting significantly from anti-PD1/PD-L1 immunotherapy clinically. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.